Sareum Holdings plc

("Sareum" or the "Company")

Exercise of Warrants

Cambridge, UK, 7 May 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received an exercise of warrants notice from RiverFort Global Opportunities PCC Ltd ("RiverFort") to subscribe for a total of 1,106,986 new ordinary shares in the capital of the Company (the "New Ordinary Shares") at a price of 10 pence per New Ordinary Share for a total consideration to the Company of £110,698.60.

As announced on 3 August 2023, the warrants were issued in connection with the Equity Prepayment Facility (the "RiverFort Facility") provided by RiverFort to the Company. Following this exercise of warrants, RiverFort hold zero warrants over shares in the Company.

As noted in Sareum's announcement of 23 April 2024, the Company has settled the full outstanding balance of, and does not intend to make any further withdrawals pursuant to, the RiverFort Facility.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange plc for the admission of the 1,106,986 New Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around Monday 13 May 2024. The New Ordinary Shares will rank pari passu with the existing ordinary shares.

Immediately following Admission, the total number of ordinary shares in issue will be 107,945,783 and the total number of voting rights will therefore be 107,945,783, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For Further Information:

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com